Unnamed: 0
int64 0
1.41M
| headline
stringlengths 3
513
| url
stringlengths 33
162
| publisher
stringlengths 3
46
| date
timestamp[s] | stock
stringlengths 1
5
|
|---|---|---|---|---|---|
1,412,021 | ZS Pharma Prices 5.9M Share IPO at $18.00/Share | https://www.benzinga.com/news/14/06/4640958/zs-pharma-prices-5-9m-share-ipo-at-18-00share | Charles Gross | 2014-06-17T00:00:00 | ZSPH |
1,412,022 | S-1MEF Filing from ZS Pharma Shows Added 1.086M Shares at Maximum Price of $18/Share | https://www.benzinga.com/news/14/06/4640830/s-1mef-filing-from-zs-pharma-shows-added-1-086m-shares-at-maximum-price-of-18shar | Paul Quintaro | 2014-06-17T00:00:00 | ZSPH |
1,412,023 | IPO Lookout: 14 IPOs For The Week Of June 16 | https://www.benzinga.com/news/14/06/4633631/ipo-lookout-14-ipos-for-the-week-of-june-16 | Charles Enser | 2014-06-16T00:00:00 | ZSPH |
1,412,024 | Stocks That Hit 52-Week Lows On Thursday | https://www.benzinga.com/news/20/03/15607641/stocks-that-hit-52-week-lows-on-thursday | Lisa Levin | 2020-03-19T14:49:42 | ZTR |
1,412,025 | Stocks That Hit 52-Week Lows On Wednesday | https://www.benzinga.com/news/20/03/15581474/stocks-that-hit-52-week-lows-on-wednesday | Benzinga Newsdesk | 2020-03-18T15:37:49 | ZTR |
1,412,026 | Stocks That Hit 52-Week Lows On Monday | https://www.benzinga.com/news/20/03/15560273/stocks-that-hit-52-week-lows-on-monday | Benzinga Newsdesk | 2020-03-16T15:51:23 | ZTR |
1,412,027 | Stocks That Hit 52-Week Lows On Thursday | https://www.benzinga.com/news/20/03/15538835/stocks-that-hit-52-week-lows-on-thursday | Lisa Levin | 2020-03-12T16:10:12 | ZTR |
1,412,028 | Stocks That Hit 52-Week Lows On Friday | https://www.benzinga.com/news/20/02/15441854/stocks-that-hit-52-week-lows-on-friday | Lisa Levin | 2020-02-28T15:16:30 | ZTR |
1,412,029 | Stocks That Hit 52-Week Highs On Friday | https://www.benzinga.com/news/20/02/15384591/stocks-that-hit-52-week-highs-on-friday | Lisa Levin | 2020-02-21T15:26:05 | ZTR |
1,412,030 | Virtus Global Dividend & Income Fund Inc. Announces Final Results Of Tender Offer | https://www.benzinga.com/news/17/06/9673339/virtus-global-dividend-income-fund-inc-announces-final-results-of-tender-offer | Hal Lindon | 2017-06-29T20:25:18 | ZTR |
1,412,031 | UPDATE: Zweig Fund And Zweig Total Return Fund Announce Increases To Distribution Rates | https://www.benzinga.com/news/16/04/7791202/update-zweig-fund-and-zweig-total-return-fund-announce-increases-to-distribution- | Hal Lindon | 2016-04-01T19:26:14 | ZTR |
1,412,032 | The Zweig Fund & Zweig Total Return Fund Approved An Increase In Annual Distribution Rate To 10% Of Fund's NAV | https://www.benzinga.com/news/16/04/7791199/the-zweig-fund-zweig-total-return-fund-approved-an-increase-in-annual-distributio | Hal Lindon | 2016-04-01T19:25:45 | ZTR |
1,412,033 | Zweig Fund, Zweig Total Return Fund Halted; Pending News | https://www.benzinga.com/news/16/04/7791185/zweig-fund-zweig-total-return-fund-halted-pending-news | Charles Gross | 2016-04-01T19:23:43 | ZTR |
1,412,034 | UPDATE: Ancora Confident New Investor Base Will Vote Differently Than Prior Base, Offers To Withdraw 14a-8 Proposal If Co. Includes One In Annual Shareholder Meeting | https://www.benzinga.com/general/hedge-funds/15/12/6082226/update-ancora-confident-new-investor-base-will-vote-differently-th | Paul Quintaro | 2015-12-30T00:00:00 | ZTR |
1,412,035 | UPDATE: Ancora Pens Letter To The Zweig Total Return Fund Board, Unable To Fathom How Below Average Performance Is Acceptable | https://www.benzinga.com/news/15/12/6082223/update-ancora-pens-letter-to-the-zweig-total-return-fund-board-unable-to-fathom-h | Paul Quintaro | 2015-12-30T00:00:00 | ZTR |
1,412,036 | Ancora Advisors Sends Letter to the Board of Directors of The Zweig Total Return Fund, Inc | https://www.benzinga.com/general/hedge-funds/15/12/6082221/ancora-advisors-sends-letter-to-the-board-of-directors-of-the-zwei | Paul Quintaro | 2015-12-30T00:00:00 | ZTR |
1,412,037 | Stifel Nicolaus Initiates Coverage on Zweig Total Return Fund, Inc. (The) Common Stock at Buy | https://www.benzinga.com/node/5673032 | Eddie Staley | 2015-07-15T00:00:00 | ZTR |
1,412,038 | Which Would You Rather, A-To-Z Version: AAR Corp or Zweig Total Return? | https://www.benzinga.com/economics/14/02/4305199/which-would-you-rather-a-to-z-version-aar-corp-or-zweig-total-return | Tabitha Jean Naylor | 2014-02-20T00:00:00 | ZTR |
1,412,039 | The Zweig Total Return Fund, Inc. Declares Distribution Of $0.032 Per Share | https://www.benzinga.com/news/11/04/970712/the-zweig-total-return-fund-inc-declares-distribution-of-0-032-per-share | Benzinga Staff | 2011-04-01T00:00:00 | ZTR |
1,412,040 | The Zweig Total Return Fund Declares Distribution of $0.033 | https://www.benzinga.com/news/11/01/747071/the-zweig-total-return-fund-declares-distribution-of-0-033 | Benzinga Staff | 2011-01-03T00:00:00 | ZTR |
1,412,041 | SmarTrend's Candlestick Scanner Detects Bullish Inside Day Pattern for Zweig Total Return Fund (ZTR) | https://www.benzinga.com/269994/smartrend-s-candlestick-scanner-detects-bullish-inside-day-pattern-for-zweig-total-return-fun | webmaster | 2010-05-10T00:00:00 | ZTR |
1,412,042 | The Zweig Total Return Fund, Inc. Discloses Sources of Distribution - Section 19A Notice | https://www.benzinga.com/09/08/1415/the-zweig-total-return-fund-inc-discloses-sources-of-distribution-section-19a-notice | Benzinga Staff | 2009-08-10T00:00:00 | ZTR |
1,412,043 | Shares of several healthcare companies are trading lower in sympathy with the overall market following an increase in coronavirus cases in some US states that have reopened, leading to concerns of a second wave of the virus. | https://www.benzinga.com/wiim/20/06/16233278/shares-of-several-healthcare-companies-are-trading-lower-in-sympathy-with-the-overall-market-followi | BenzingaâNewsdesk | 2020-06-11T14:22:31 | ZTS |
1,412,044 | UBS Maintains Neutral on Zoetis, Lowers Price Target to $126 | https://www.benzinga.com/news/20/05/15992038/ubs-maintains-neutral-on-zoetis-lowers-price-target-to-126 | Benzinga_Newsdesk | 2020-05-08T18:23:47 | ZTS |
1,412,045 | Citigroup Maintains Neutral on Zoetis, Lowers Price Target to $131 | https://www.benzinga.com/news/20/05/15988559/citigroup-maintains-neutral-on-zoetis-lowers-price-target-to-131 | Vick Meyer | 2020-05-08T12:33:35 | ZTS |
1,412,046 | Barclays Maintains Overweight on Zoetis, Raises Price Target to $140 | https://www.benzinga.com/news/20/05/15979562/barclays-maintains-overweight-on-zoetis-raises-price-target-to-140 | Benzinga_Newsdesk | 2020-05-07T15:17:30 | ZTS |
1,412,047 | Zoetis shares are trading lower after the company issued FY20 EPS and sales guidance below analyst estimates. | https://www.benzinga.com/wiim/20/05/15966556/zoetis-shares-are-trading-lower-after-the-company-issued-fy20-eps-and-sales-guidance-below-analyst-e | Benzinga Newsdesk | 2020-05-06T13:03:51 | ZTS |
1,412,048 | The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle | https://www.benzinga.com/general/biotech/20/05/15965174/the-daily-biotech-pulse-fda-nod-for-astrazeneca-abbvie-allergan-deal-clears-antitrust-hurdle | Shanthi Rexaline | 2020-05-06T12:42:07 | ZTS |
1,412,049 | Zoetis Sees FY20 Adj. EPS $3.17-$3.42 vs $3.71 Est., Sales $5.95B-$6.25B vs $6.43B Est. | https://www.benzinga.com/news/20/05/15964747/zoetis-sees-fy20-adj-eps-3-17-3-42-vs-3-71-est-sales-5-95b-6-25b-vs-6-43b-est | Benzinga Newsdesk | 2020-05-06T11:05:20 | ZTS |
1,412,050 | Zoetis Q1 Adj. EPS $0.950 Beats $0.860 Estimate, Sales $1.500B Inline | https://www.benzinga.com/news/earnings/20/05/15964717/zoetis-q1-adj-eps-0-950-beats-0-860-estimate-sales-1-500b-inline | Benzinga Newsdesk | 2020-05-06T11:03:58 | ZTS |
1,412,051 | Earnings Scheduled For May 6, 2020 | https://www.benzinga.com/news/earnings/20/05/15963874/earnings-scheduled-for-may-6-2020 | Lisa Levin | 2020-05-06T08:36:09 | ZTS |
1,412,052 | Shares of several healthcare companies are trading higher amid positive investor sentiment as some US states begin to reopen their economies and as oil prices gain for the session. | https://www.benzinga.com/wiim/20/05/15957697/shares-of-several-healthcare-companies-are-trading-higher-amid-positive-investor-sentiment-as-some-u | Benzinga Newsdesk | 2020-05-05T16:44:19 | ZTS |
1,412,053 | The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace | https://www.benzinga.com/general/biotech/20/05/15926105/the-week-ahead-in-biotech-smid-cap-earnings-news-flow-picks-up-pace | Shanthi Rexaline | 2020-05-03T00:00:00 | ZTS |
1,412,054 | Three High-Quality Companies To Bet On In A Post-Coronavirus World | https://www.benzinga.com/opinion/20/04/15884380/three-high-quality-companies-to-bet-on-in-a-post-coronavirus-world | IAM Newswire | 2020-04-29T00:00:00 | ZTS |
1,412,055 | Shares of several healthcare companies are trading lower with the overall market on continued downward momentum after oil prices fell to historic lows, partially stemming from weak demand caused by the coronavirus pandemic. | https://www.benzinga.com/wiim/20/04/15849176/shares-of-several-healthcare-companies-are-trading-lower-with-the-overall-market-on-continued-downwa | Benzinga Newsdesk | 2020-04-21T00:00:00 | ZTS |
1,412,056 | FDA Says Closely Monitoring Potential For New Animal Drug Shortages And Supply Chain Disruptions | https://www.benzinga.com/news/20/04/15822560/fda-says-closely-monitoring-potential-for-new-animal-drug-shortages-and-supply-chain-disruptions | Benzinga Newsdesk | 2020-04-16T00:00:00 | ZTS |
1,412,057 | Shares of several healthcare companies are trading higher as markets gain on positive coronavirus outlook. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic. | https://www.benzinga.com/wiim/20/04/15798567/shares-of-several-healthcare-companies-are-trading-higher-as-markets-gain-on-positive-coronavirus-ou | Benzinga Newsdesk | 2020-04-14T00:00:00 | ZTS |
1,412,058 | Shares of several healthcare companies are trading lower amid overall market weakness. Stocks are lower, selling off from last week's gains amid uncertainty surrounding coronavirus outlook and the reopening of the economy. | https://www.benzinga.com/wiim/20/04/15790339/shares-of-several-healthcare-companies-are-trading-lower-amid-overall-market-weakness-stocks-are-low | Benzinga Newsdesk | 2020-04-13T00:00:00 | ZTS |
1,412,059 | Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several US hotspots may be peaking. A sooner peak could mean a sooner return to economic activity. | https://www.benzinga.com/wiim/20/04/15748126/shares-of-several-healthcare-companies-are-trading-higher-as-markets-gain-amid-optimism-that-coronav | Benzinga Newsdesk | 2020-04-06T00:00:00 | ZTS |
1,412,060 | Morgan Stanley Maintains Equal-Weight on Zoetis, Lowers Price Target to $125 | https://www.benzinga.com/news/20/04/15727615/morgan-stanley-maintains-equal-weight-on-zoetis-lowers-price-target-to-125 | Vick Meyer | 2020-04-02T00:00:00 | ZTS |
1,412,061 | Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities. | https://www.benzinga.com/wiim/20/04/15717065/shares-of-several-healthcare-companies-are-trading-lower-amid-market-weakness-as-growing-coronavirus | Benzinga Newsdesk | 2020-04-01T00:00:00 | ZTS |
1,412,062 | Shares of several healthcare companies are trading higher as the market rebounds on extended measures to help curb the coronavirus. NOTE: The sector could also be trading higher due to increased demand for medical products amid the coronavirus outbreak. | https://www.benzinga.com/wiim/20/03/15695285/shares-of-several-healthcare-companies-are-trading-higher-as-the-market-rebounds-on-extended-measure | Benzinga Newsdesk | 2020-03-30T00:00:00 | ZTS |
1,412,063 | Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak. | https://www.benzinga.com/wiim/20/03/15683827/shares-of-several-healthcare-companies-are-trading-lower-selling-off-from-this-weeks-strength-while | Benzinga Newsdesk | 2020-03-27T00:00:00 | ZTS |
1,412,064 | The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test | https://www.benzinga.com/general/biotech/20/03/15648204/the-daily-biotech-pulse-milestone-pharma-flunks-late-stage-study-cytomx-strikes-cancer-drug-colla | Shanthi Rexaline | 2020-03-24T00:00:00 | ZTS |
1,412,065 | Stocks That Hit 52-Week Lows On Monday | https://www.benzinga.com/news/20/03/15635758/stocks-that-hit-52-week-lows-on-monday | Lisa Levin | 2020-03-23T00:00:00 | ZTS |
1,412,066 | The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection | https://www.benzinga.com/general/biotech/20/03/15604319/the-daily-biotech-pulse-pfizers-eczema-drug-aces-latestage-study-orphan-drug-designation-for-dice | Shanthi Rexaline | 2020-03-19T00:00:00 | ZTS |
1,412,067 | Zoetis Shares Up 5% After Hours; SunTrust Earlier Discussed Expectations Drugmakers Won't See Near-Term Debt Crisis, Sees Co., Jazz Pharma As Strongest Positioned In Terms Of Debt, Leverage | https://www.benzinga.com/analyst-ratings/analyst-color/20/03/15585257/zoetis-shares-up-5-after-hours-suntrust-earlier-discussed-expectations-drugmakers-w | Benzinga Newsdesk | 2020-03-18T00:00:00 | ZTS |
1,412,068 | Shares of several healthcare companies are trading lower as the coronavirus outbreak continues to cause economic disruption around the globe, leading to a steep selloff in equities across sectors. | https://www.benzinga.com/wiim/20/03/15559452/shares-of-several-healthcare-companies-are-trading-lower-as-the-coronavirus-outbreak-continues-to-ca | Benzinga Newsdesk | 2020-03-16T00:00:00 | ZTS |
1,412,069 | Shares of several healthcare companies are trading lower. Movement appears market-related as markets continue to dip amid the global coronavirus outbreak and OPEC failing to reach production agreement. | https://www.benzinga.com/wiim/20/03/15508124/shares-of-several-healthcare-companies-are-trading-lower-movement-appears-market-related-as-markets | Benzinga Newsdesk | 2020-03-09T00:00:00 | ZTS |
1,412,070 | Shares of several healthcare companies are trading lower. Movement appears market related as markets continue to dip amid the global coronavirus outbreak. | https://www.benzinga.com/wiim/20/03/15497311/shares-of-several-healthcare-companies-are-trading-lower-movement-appears-market-related-as-markets | Benzinga Newsdesk | 2020-03-06T00:00:00 | ZTS |
1,412,071 | Shares of several healthcare companies are trading higher in sympathy with the overall market as it rebounds from a selloff caused by coronavirus fears. | https://www.benzinga.com/wiim/20/03/15456786/shares-of-several-healthcare-companies-are-trading-higher-in-sympathy-with-the-overall-market-as-it | Benzinga Newsdesk | 2020-03-02T00:00:00 | ZTS |
1,412,072 | Zoetis Receives FDA Approval For Simparica Trio, A New Combination Parasite Preventative For Dogs | https://www.benzinga.com/news/20/02/15432491/zoetis-receives-fda-approval-for-simparica-trio-a-new-combination-parasite-preventative-for-dogs | Benzinga Newsdesk | 2020-02-27T00:00:00 | ZTS |
1,412,073 | Shares of several healthcare and biotech companies are trading higher. Not seeing any news to justify the price action. | https://www.benzinga.com/wiim/20/02/15420478/shares-of-several-healthcare-and-biotech-companies-are-trading-higher-not-seeing-any-news-to-justify | Benzinga Newsdesk | 2020-02-26T00:00:00 | ZTS |
1,412,074 | Shares of several healthcare and biotech companies are trading higher. Movement appears market related as equities have rebounded this session following recent selloffs. | https://www.benzinga.com/wiim/20/02/15418358/shares-of-several-healthcare-and-biotech-companies-are-trading-higher-movement-appears-market-relate | Benzinga Newsdesk | 2020-02-26T00:00:00 | ZTS |
1,412,075 | UBS Maintains Neutral on Zoetis, Raises Price Target to $146 | https://www.benzinga.com/news/20/02/15363093/ubs-maintains-neutral-on-zoetis-raises-price-target-to-146 | Vick Meyer | 2020-02-19T00:00:00 | ZTS |
1,412,076 | Morgan Stanley Maintains Equal-Weight on Zoetis, Raises Price Target to $148 | https://www.benzinga.com/news/20/02/15336245/morgan-stanley-maintains-equal-weight-on-zoetis-raises-price-target-to-148 | Vick Meyer | 2020-02-14T00:00:00 | ZTS |
1,412,077 | The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering | https://www.benzinga.com/general/biotech/20/02/15334758/the-daily-biotech-pulse-epizymes-tazemetostat-snda-accepted-for-priority-review-eisai-to-withdraw | Shanthi Rexaline | 2020-02-14T00:00:00 | ZTS |
1,412,078 | Zoetis shares are trading higher after the company reported better-than-expected Q4 EPS and sales results. | https://www.benzinga.com/wiim/20/02/15328179/zoetis-shares-are-trading-higher-after-the-company-reported-better-than-expected-q4-eps-and-sales-re | Benzinga Newsdesk | 2020-02-13T00:00:00 | ZTS |
1,412,079 | CFRA Upgrades Zoetis to Strong Buy, Raises Price Target to $160 | https://www.benzinga.com/news/20/02/15326639/cfra-upgrades-zoetis-to-strong-buy-raises-price-target-to-160 | Benzinga_Newsdesk | 2020-02-13T00:00:00 | ZTS |
1,412,080 | The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO | https://www.benzinga.com/general/biotech/20/02/15322179/the-daily-biotech-pulse-deciphera-cancer-drug-gets-priority-review-fast-track-designation-for-sol | Shanthi Rexaline | 2020-02-13T00:00:00 | ZTS |
1,412,081 | Zoetis Sees FY20 Adj. EPS $3.90-$4 vs $4.01 Estimate, Sales $6.65B-$6.8B vs $6.7B Est. | https://www.benzinga.com/news/20/02/15321706/zoetis-sees-fy20-adj-eps-3-90-4-vs-4-01-estimate-sales-6-65b-6-8b-vs-6-7b-est | Benzinga Newsdesk | 2020-02-13T00:00:00 | ZTS |
1,412,082 | Zoetis Q4 Adj. EPS $0.92 Beats $0.88 Estimate, Sales $1.674B Beat $1.64B Estimate | https://www.benzinga.com/news/earnings/20/02/15321702/zoetis-q4-adj-eps-0-92-beats-0-88-estimate-sales-1-674b-beat-1-64b-estimate | Benzinga Newsdesk | 2020-02-13T00:00:00 | ZTS |
1,412,083 | Earnings Scheduled For February 13, 2020 | https://www.benzinga.com/news/earnings/20/02/15320570/earnings-scheduled-for-february-13-2020 | Lisa Levin | 2020-02-13T00:00:00 | ZTS |
1,412,084 | The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data | https://www.benzinga.com/general/biotech/20/02/15308201/the-daily-biotech-pulse-j-j-intensifies-efforts-on-covid-19-cure-adamas-reports-positive-long-ter | Shanthi Rexaline | 2020-02-12T00:00:00 | ZTS |
1,412,085 | Stocks That Hit 52-Week Highs On Tuesday | https://www.benzinga.com/news/20/02/15300466/stocks-that-hit-52-week-highs-on-tuesday | Lisa Levin | 2020-02-11T00:00:00 | ZTS |
1,412,086 | The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight | https://www.benzinga.com/general/biotech/20/02/15280585/the-week-ahead-in-biotech-smid-cap-earnings-in-the-spotlight | Shanthi Rexaline | 2020-02-09T00:00:00 | ZTS |
1,412,087 | Shares of several healthcare companies are trading lower as fears of the coronavirus' potential impact on the global economy intensifies. The death toll continues to rise and the U.K. and Russia confirmed their first cases. | https://www.benzinga.com/wiim/20/01/15228528/shares-of-several-healthcare-companies-are-trading-lower-as-fears-of-the-coronavirus-potential-impac | Benzinga Newsdesk | 2020-01-31T00:00:00 | ZTS |
1,412,088 | Zoetis shares are trading lower. Not seeing any news to justify the price action. | https://www.benzinga.com/wiim/20/01/15173870/zoetis-shares-are-trading-lower-not-seeing-any-news-to-justify-the-price-action | Benzinga Newsdesk | 2020-01-23T00:00:00 | ZTS |
1,412,089 | The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment | https://www.benzinga.com/general/biotech/20/01/15169823/the-daily-biotech-pulse-roche-reports-positive-sma-data-readout-vir-biotech-to-work-on-virus-trea | Shanthi Rexaline | 2020-01-23T00:00:00 | ZTS |
1,412,090 | Stocks That Hit 52-Week Highs On Wednesday | https://www.benzinga.com/news/20/01/15163983/stocks-that-hit-52-week-highs-on-wednesday | Lisa Levin | 2020-01-22T00:00:00 | ZTS |
1,412,091 | The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings | https://www.benzinga.com/general/biotech/20/01/15161635/the-daily-biotech-pulse-johnson-johnson-earnings-fda-nod-for-horizon-therapeutics-slew-of-seconda | Shanthi Rexaline | 2020-01-22T00:00:00 | ZTS |
1,412,092 | Stocks That Hit 52-Week Highs On Tuesday | https://www.benzinga.com/news/20/01/15155396/stocks-that-hit-52-week-highs-on-tuesday | Lisa Levin | 2020-01-21T00:00:00 | ZTS |
1,412,093 | Stocks That Hit 52-Week Highs On Friday | https://www.benzinga.com/news/20/01/15144632/stocks-that-hit-52-week-highs-on-friday | Lisa Levin | 2020-01-17T00:00:00 | ZTS |
1,412,094 | The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares | https://www.benzinga.com/general/biotech/20/01/15141617/the-daily-biotech-pulse-novo-nordisks-ozempic-receives-label-expansion-for-cardiovascular-events- | Shanthi Rexaline | 2020-01-17T00:00:00 | ZTS |
1,412,095 | Stocks That Hit 52-Week Highs On Thursday | https://www.benzinga.com/news/20/01/15135505/stocks-that-hit-52-week-highs-on-thursday | Lisa Levin | 2020-01-16T00:00:00 | ZTS |
1,412,096 | The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics | https://www.benzinga.com/general/biotech/20/01/15133299/the-daily-biotech-pulse-osmotica-soars-on-insider-buys-ultragenyxs-partnered-rare-disease-drug-mo | Shanthi Rexaline | 2020-01-16T00:00:00 | ZTS |
1,412,097 | Stocks That Hit 52-Week Highs On Wednesday | https://www.benzinga.com/news/20/01/15129364/stocks-that-hit-52-week-highs-on-wednesday | Lisa Levin | 2020-01-15T00:00:00 | ZTS |
1,412,098 | The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance | https://www.benzinga.com/general/biotech/20/01/15125323/the-daily-biotech-pulse-nektar-withdraws-opioid-pain-drug-nda-galapagos-takes-stake-in-fibrocor-i | Shanthi Rexaline | 2020-01-15T00:00:00 | ZTS |
1,412,099 | The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug | https://www.benzinga.com/general/biotech/20/01/15117688/the-daily-biotech-pulse-phasebio-to-buy-hypertension-asset-stemline-falls-on-q4-pre-announcement- | Shanthi Rexaline | 2020-01-14T00:00:00 | ZTS |
1,412,100 | Benzinga's Top Upgrades, Downgrades For January 10, 2020 | https://www.benzinga.com/analyst-ratings/upgrades/20/01/15106352/benzingas-top-upgrades-downgrades-for-january-10-2020 | Lisa Levin | 2020-01-10T00:00:00 | ZTS |
1,412,101 | Raymond James Initiates Coverage On Zoetis with Market Perform Rating | https://www.benzinga.com/news/20/01/15104626/raymond-james-initiates-coverage-on-zoetis-with-market-perform-rating | Benzinga Newsdesk | 2020-01-10T00:00:00 | ZTS |
1,412,102 | The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx | https://www.benzinga.com/general/biotech/20/01/15103285/the-daily-biotech-pulse-positive-data-readouts-to-spur-aclaris-moderna-and-ultragenyx | Shanthi Rexaline | 2020-01-10T00:00:00 | ZTS |
1,412,103 | Stocks That Hit 52-Week Highs On Thursday | https://www.benzinga.com/news/20/01/15101221/stocks-that-hit-52-week-highs-on-thursday | Lisa Levin | 2020-01-09T00:00:00 | ZTS |
1,412,104 | The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results | https://www.benzinga.com/general/biotech/20/01/15097311/the-daily-biotech-pulse-mercks-keytruda-snags-another-fda-approval-dbv-announces-positive-peanut- | Shanthi Rexaline | 2020-01-09T00:00:00 | ZTS |
1,412,105 | The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger | https://www.benzinga.com/m-a/20/01/15065464/the-daily-biotech-pulse-acorda-surges-as-point72-hikes-stake-novan-sinks-on-failed-study-illumina-pa | Shanthi Rexaline | 2020-01-03T00:00:00 | ZTS |
1,412,106 | Stocks That Hit 52-Week Highs On Friday | https://www.benzinga.com/news/19/12/15026655/stocks-that-hit-52-week-highs-on-friday | Lisa Levin | 2019-12-20T00:00:00 | ZTS |
1,412,107 | Zoetis shares are trading higher. The stock moved higher following unusual interest in the July $140 call contract. | https://www.benzinga.com/wiim/19/12/15026590/zoetis-shares-are-trading-higher-the-stock-moved-higher-following-unusual-interest-in-the-july-140-c | Benzinga Newsdesk | 2019-12-20T00:00:00 | ZTS |
1,412,108 | Zoetis Raises Quarterly Dividend From $0.164 To $0.20/Share | https://www.benzinga.com/news/19/12/14975489/zoetis-raises-quarterly-dividend-from-0-164-to-0-20share | Benzinga Newsdesk | 2019-12-11T00:00:00 | ZTS |
1,412,109 | Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data. | https://www.benzinga.com/wiim/19/12/14913297/shares-of-several-healthcare-stocks-are-trading-lower-as-us-equities-dip-following-escalating-us-chi | Benzinga Newsdesk | 2019-12-02T00:00:00 | ZTS |
1,412,110 | Zoetis Reports Purchase Of ZNLabs, No Terms Disclosed | https://www.benzinga.com/m-a/19/11/14865251/zoetis-reports-purchase-of-znlabs-no-terms-disclosed | Benzinga Newsdesk | 2019-11-22T00:00:00 | ZTS |
1,412,111 | Boring No More: Agriculture and Food Investing Gets A Sexy New ETF | https://www.benzinga.com/trading-ideas/long-ideas/19/11/14817674/boring-no-more-agriculture-and-food-investing-gets-a-sexy-new-etf | ETF Professor | 2019-11-15T00:00:00 | ZTS |
1,412,112 | Zoetis shares are trading lower despite the company reporting better-than-expected Q3 EPS and sales results. | https://www.benzinga.com/wiim/19/11/14769459/zoetis-shares-are-trading-lower-despite-the-company-reporting-better-than-expected-q3-eps-and-sales | Benzinga Newsdesk | 2019-11-08T00:00:00 | ZTS |
1,412,113 | JP Morgan Maintains Overweight on Zoetis, Raises Price Target to $150 | https://www.benzinga.com/news/19/11/14767237/jp-morgan-maintains-overweight-on-zoetis-raises-price-target-to-150 | Vick Meyer | 2019-11-08T00:00:00 | ZTS |
1,412,114 | Morgan Stanley Upgrades Elanco Animal Health On Valuation | https://www.benzinga.com/analyst-ratings/analyst-color/19/11/14757925/morgan-stanley-upgrades-elanco-animal-health-on-valuation | Priya Nigam | 2019-11-07T00:00:00 | ZTS |
1,412,115 | Zoetis Sees FY19 Guidance: Adj. EPS $3.57-$3.62 vs $3.57 Estimate, Sales $6.2B-$6.25B vs $6.24B Est. | https://www.benzinga.com/news/19/11/14755104/zoetis-sees-fy19-guidance-adj-eps-3-57-3-62-vs-3-57-estimate-sales-6-2b-6-25b-vs-6-24b-est | Benzinga Newsdesk | 2019-11-07T00:00:00 | ZTS |
1,412,116 | Zoetis Q3 EPS $0.94 Beats $0.88 Estimate, Sales $1.584B Beat $1.58B Estimate | https://www.benzinga.com/news/earnings/19/11/14755068/zoetis-q3-eps-0-94-beats-0-88-estimate-sales-1-584b-beat-1-58b-estimate | Benzinga Newsdesk | 2019-11-07T00:00:00 | ZTS |
1,412,117 | The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs | https://www.benzinga.com/general/biotech/19/11/14752971/the-daily-biotech-pulse-obseva-sinks-on-adverse-clinical-readout-bionano-surges-on-saphyr-adoptio | Shanthi Rexaline | 2019-11-07T00:00:00 | ZTS |
1,412,118 | Earnings Scheduled For November 7, 2019 | https://www.benzinga.com/news/earnings/19/11/14752780/earnings-scheduled-for-november-7-2019 | Lisa Levin | 2019-11-07T00:00:00 | ZTS |
1,412,119 | A Preview Of Zoetis' Q3 Earnings | https://www.benzinga.com/news/earnings-previews/19/11/14747208/a-preview-of-zoetiss-earnings | Benzinga Newsdesk | 2019-11-06T00:00:00 | ZTS |
1,412,120 | Zoetis shares are trading lower in sympathy with Mylan after the company reported worse-than-expected sales and issued inline guidance. | https://www.benzinga.com/markets/wiim/19/11/14733811/zoetis-shares-are-trading-lower-in-sympathy-with-mylan-after-the-company-reported-worse-than-expecte | Benzinga Newsdesk | 2019-11-05T00:00:00 | ZTS |